Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
FDA Opens Up A New Path To The U.S. Market For This Under 30 Biotech Startup
More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
Journey Medical: FDA Approval For Emrosi Makes This An Exciting Stock
The approval Journey Medical received from FDA for Emrosi makes DERM an exciting stock. Click here to read more.
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Winston-Salem Journal17h
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
As Trump and RFK Jr. move to upend drug making, Seattle biotech bets on science
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...